ArticleAntimicrobial agents and chemotherapy2011
Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
180 citing papers in PubMed, 3 syntheses or guidelines pooled it, 331 citations in OpenAlex.
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Guideline
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Guideline
- Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.The European respiratory journal · 2020Guideline
- In vitro and in vivo antibacterial activity of pravibismane against Mycobacteroides abscessus.BMC microbiology · 2026Article
- Benchmarking deep learning architectures for MALDI-TOF mass spectrometry in infectious disease diagnostics and vector-borne disease surveillance.NPJ digital medicine · 2026Article
- Toward Robust Machine Learning Models for MALDI-TOF MS: Novel Approaches forJournal of proteome research · 2026Article
- Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes.Nature microbiology · 2026Article
- Genome and drug resistance analysis ofFrontiers in microbiology · 2026Article
- Challenges in the Diagnosis and Treatment of Mycobacterium abscessus Infections.Revista da Sociedade Brasileira de Medicina Tropical · 2026Review
- Clinical emergence of inducible macrolide resistance mediated by acquiredAntimicrobial agents and chemotherapy · 2025Article
- Pathogenicity and virulence ofVirulence · 2025Review
- Luciferase reporter mycobacteriophage (TM4::Journal of clinical microbiology · 2025Article
- Evaluation of mlstverse system for accurate subspecies identification and drug resistance prediction inMicrobiology spectrum · 2025Article
- Series 1: The Use ofTropical medicine and infectious disease · 2025Article
- Limited predictive power of known resistance genes for phenotypic drug resistance in clinicalAntimicrobial agents and chemotherapy · 2025Article
- Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan.Microbiology spectrum · 2025Article
- Review
- Mycobacteroides abscessus subspecies: a comparative genomic analysis reveals unique metabolic activities and drug resistance patterns.BMC microbiology · 2025Article
- Subspecies distribution and drug-resistance characteristics ofMicrobiology spectrum · 2025Article
- Macrolide resistance inJAC-antimicrobial resistance · 2025Review
120 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clarithromycin was the drug of choice for Mycobacterium abscessus infections until inducible resistance due to erm(41) was described. Because M. abscessus was split into M. abscessus sensu stricto, Mycobacterium massiliense, and Mycobacterium bolletii, we looked for erm(41) in the three species and determined their clarithromycin susceptibility levels. Ninety strains were included: 87 clinical strains from cystic fibrosis patients (61%) and others (39%), representing 43 M. abscessus, 30 M. massiliense, and 14 M. bolletii strains identified on a molecular basis, and 3 reference strains. Clarithromycin and azithromycin MICs were determined by broth microdilution and Etest with a 14-day incubation period. Mutations in rrl (23S rRNA gene) known to confer acquired clarithromycin resistance were also sought. erm(41) was detected in all strains but with two deletions in all M. massiliense strains. These strains were indeed susceptible to clarithromycin (MIC(90) of 1 μg/ml) except for four strains with rrl mutations. M. abscessus strains harbored an intact erm(41) but had a T/C polymorphism at the 28th nucleotide: T28 strains (Trp10 codon) demonstrated inducible clarithromycin resistance (MIC(90) of >16 μg/ml), while C28 strains (Arg10) were susceptible (MIC(90) of 2 μg/ml) except for two strains with rrl mutations. M. bolletii strains had erm(41) sequences similar to the sequence of the T28 M. abscessus group, associated with inducible clarithromycin resistance (MIC(90) of >16 μg/ml). erm(41) sequences appeared species specific within the M. abscessus group and were fully concordant with clarithromycin susceptibility when erm(41) sequencing was associated with detection of rrl mutations. Clarithromycin-resistant strains, including the six rrl mutants, were more often isolated in cystic fibrosis patients, but this was not significantly associated with a previous treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.